Jonathan P. Foster - 16 Jun 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan P. Foster
Issuer symbol
MBRX
Transactions as of
16 Jun 2023
Transactions value $
-$5,515
Form type
4
Filing time
22 Jun 2023, 19:02:04 UTC
Previous filing
16 Mar 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +40.7K +197.61% 61.2K 20 Jun 2023 Direct F1
transaction MBRX Common Stock Tax liability -$5.52K -9.68K -15.8% $0.57 51.6K 20 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -40.7K -5.64% $0.00 681K 20 Jun 2023 Common Stock 40.7K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 20, 2022, the reporting person was granted 162,667 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.